Lescol (fluvastatin sodium)

Company
Novartis

Approval Status
Approved September 1997

Treatment for
coronary atherosclerosis

Possible similar drugs
Lescol; Lescol XL

Areas
Cardiovascular / Cardiology , Diabetes / Endocrinology

Lescol has been approved for a new indication--a treatment to decrease the progression of coronary atherosclerosis in patients with coronary heart disease undergoing treatment programs to lower lipoprotein cholesterol. Lescol was originally approved in 1994 for patients with primary hypercholesterolemia.

Lescol (fluvastatin sodium) Drug Information

The Lescol (fluvastatin sodium) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top